Ontology highlight
ABSTRACT:
SUBMITTER: Pardridge WM
PROVIDER: S-EPMC7697739 | biostudies-literature | 2020 Nov
REPOSITORIES: biostudies-literature
Pharmaceuticals (Basel, Switzerland) 20201116 11
Despite the enormity of the societal and health burdens caused by Alzheimer's disease (AD), there have been no FDA approvals for new therapeutics for AD since 2003. This profound lack of progress in treatment of AD is due to dual problems, both related to the blood-brain barrier (BBB). First, 98% of small molecule drugs do not cross the BBB, and ~100% of biologic drugs do not cross the BBB, so BBB drug delivery technology is needed in AD drug development. Second, the pharmaceutical industry has ...[more]